TMO Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $25 billion. Its Mission is to enable our customers to make the world healthier, cleaner and safer. Whether the customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, the company is here to support them. Its global team of more than 75,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon.

Company profile

Marc Casper
Fiscal year end
Former names
IRS number

TMO stock data


Investment data

Data from SEC filings
Securities sold
Number of investors


7 May 21
17 Jun 21
31 Dec 21
Quarter (USD)
Apr 21 Dec 20 Sep 20 Jun 20
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 5.6B 5.6B 5.6B 5.6B 5.6B 5.6B
Cash burn (monthly) 1.58B (positive/no burn) (positive/no burn) (positive/no burn) (positive/no burn) (positive/no burn)
Cash used (since last report) 3.88B n/a n/a n/a n/a n/a
Cash remaining 1.72B n/a n/a n/a n/a n/a
Runway (months of cash) 1.1 n/a n/a n/a n/a n/a

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
19 May 21 Weisler Dion J Common Stock Grant Aquire A No No 0 438 0 3,561
19 May 21 Spar Debora L Common Stock Grant Aquire A No No 0 438 0 1,010
19 May 21 Sperling Scott M Common Stock Grant Aquire A No No 0 438 0 75,701
19 May 21 Manzi Jim P Common Stock Grant Aquire A No No 0 438 0 18,324
19 May 21 R. Alexandra Keith Common Stock Grant Aquire A No No 0 438 0 438

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

85.9% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 1967 1982 -0.8%
Opened positions 135 270 -50.0%
Closed positions 150 98 +53.1%
Increased positions 802 724 +10.8%
Reduced positions 741 724 +2.3%
13F shares
Current Prev Q Change
Total value 153.87B 161.72B -4.9%
Total shares 337.65M 347.19M -2.7%
Total puts 1.73M 2.42M -28.7%
Total calls 2.51M 2M +25.7%
Total put/call ratio 0.7 1.2 -43.3%
Largest owners
Shares Value Change
Vanguard 30.85M $14.08B -0.5%
BLK Blackrock 29.31M $13.38B -0.7%
Capital World Investors 16.74M $7.64B +4.7%
STT State Street 15.23M $6.96B -3.4%
Massachusetts Financial Services 12.31M $5.62B -3.4%
FMR 11.97M $5.47B -8.0%
TROW T. Rowe Price 11.18M $5.1B -11.0%
Capital Research Global Investors 8.85M $4.04B -10.9%
MS Morgan Stanley 8.29M $3.78B +7.3%
BAC Bank Of America 6.26M $2.86B -6.4%
Largest transactions
Shares Bought/sold Change
Norges Bank 0 -5.02M EXIT
Wellington Management 5.16M -2.14M -29.2%
TROW T. Rowe Price 11.18M -1.38M -11.0%
Capital Research Global Investors 8.85M -1.08M -10.9%
FMR 11.97M -1.05M -8.0%
Swedbank 0 -991.28K EXIT
Viking Global Investors 861.89K +784.07K +1007.6%
Capital World Investors 16.74M +757.67K +4.7%
Baillie Gifford & Co 1.45M -727.2K -33.3%
MKFCF Mackenzie Financial 943.14K +629.47K +200.7%

Financial report summary

Management Discussion
  • Item 2.    Management’s Discussion and Analysis of Financial Condition and Results of Operations
  • Forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934 are made throughout this Management’s Discussion and Analysis of Financial Condition and Results of Operations. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements, including without limitation statements regarding: projections of revenues, expenses, earnings, margins, tax rates, tax provisions, cash flows, pension and benefit obligations and funding requirements, our liquidity position; cost reductions, restructuring activities, new product and service developments, competitive strengths or market position, acquisitions or divestitures; growth, declines and other trends in markets we sell into; new or modified laws, regulations and accounting pronouncements; outstanding claims, legal proceedings, tax audits and assessments and other contingent liabilities; foreign currency exchange rates and fluctuations in those rates; general economic and capital markets conditions; the timing of any of the foregoing; assumptions underlying any of the foregoing; the expected impact of the COVID-19 pandemic on the company’s business; and any other statements that address events or developments that Thermo Fisher intends or believes will or may occur in the future. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “seeks,” “estimates,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements are accompanied by such words. While the company may elect to update forward-looking statements in the future, it specifically disclaims any obligation to do so, even if the company’s estimates change, and readers should not rely on those forward-looking statements as representing the company’s views as of any date subsequent to the date of the filing of this Quarterly Report.
  • Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are set forth under the caption “Risk Factors” in the company’s Annual Report on Form 10-K for the year ended December 31, 2020 (which is on file with the SEC) as updated under the heading “Risk Factors” in Part II, Item 1A of this report on Form 10-Q. Important factors that could cause actual results to differ materially from those indicated by forward-looking statements include risks and uncertainties relating to: the duration and severity of the COVID-19 pandemic; the need to develop new products and adapt to significant technological change; implementation of strategies for improving growth; general economic conditions and related uncertainties, dependence on customers' capital spending policies and government funding policies; the effect of economic and political conditions and exchange rate fluctuations on international operations; use and protection of intellectual property; the effect of changes in governmental regulations; any natural disaster, public health crisis or other catastrophic event; and the effect of laws and regulations governing government contracts, as well as the possibility that expected benefits related to recent or pending acquisitions, including our pending acquisition of PPD, Inc., may not materialize as expected.
Content analysis
8th grade Avg
New words: area, attempt, biopharma, biotechnology, capability, care, check, chromatography, code, condensed, consent, distributor, emerging, enable, extra, February, fewer, filer, Identification, incorporation, LIBOR, likelihood, mark, Mesa, Novasep, PCR, pendency, platform, polymerase, PPD, preceding, preliminary, Qualitative, Quantitative, reaction, Registrant, robust, SAS, shell, smaller, sorting, spectrometry, submitted, successor, telephone, Title, TMO, Unregistered, Washington, York
Removed: abandoned, actuarially, adjusted, advance, aged, alleged, alleging, allocate, amended, amortized, Anatomical, anticipation, apparent, apply, asserted, augment, August, authorized, billed, Bio, Brammer, California, charged, clarification, clarify, classified, closure, coincide, collected, comparison, complaint, conclusion, conform, contingently, convert, core, corporate, corporation, Court, decreased, delinquency, deliver, delivered, determination, determining, discontinue, discontinuing, disposal, District, divested, divestiture, dollar, doubtful, effectively, effort, entity, equal, estate, evaluate, experienced, facilitate, forward, inability, infringement, injunctive, input, installed, interaction, invoice, invoiced, IP, July, June, knowledge, lapse, leading, liable, maintenance, maximum, measure, mitigate, modify, month, monthly, observable, occurred, offering, organization, outlay, patent, Pathology, PHC, Plaintiff, planned, planning, postretirement, QIAGEN, readily, real, receive, recovered, reimbursement, relevant, relief, requiring, reset, retained, retrospective, safety, sensitive, September, significance, significantly, similarly, software, Southern, sponsor, spread, standard, strain, streamline, streamlining, subsidiary, supply, supportable, termination, unasserted, unconditional, understand, Unisone, United, variable, warranty